NCEL
NewcelX Ltd.
NASDAQ: NCEL · HEALTHCARE · BIOTECHNOLOGY
$3.33
-6.98% today
Updated 2026-06-05
Market cap
$18.74M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.16
Dividend yield
—
52W range
$2 – $31
Volume
0.1M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.0
Quality
C3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-2.77M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-16.50M | $-12.17M | $-1.98M | $-8.30M | $-8.30M |
| EPS | — | — | — | — | $-2.16 |
| Free cash flow | $-14.52M | $-9.68M | $-4.27M | $-2.77M | $-2.77M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
NewcelX Ltd. trades at $3.33. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.
Frequently asked questions
What is NewcelX Ltd.'s stock price?
NewcelX Ltd. (NCEL) trades at $3.33.
Is NewcelX Ltd. overvalued?
NewcelX Ltd. carries a Smart Value Score of 22/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-58.01%
Beta0.57
50D MA$3.04
200D MA$7.63
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—